All Videos

Emily Ruiz, MD and Todd Schlesinger, MD discuss treatment options for locally advanced basal cell carcinoma, such as immunotherapy and surgery.

Lauren Miller, MPAS, and Tj Chao, MPAS, offer considerations for treating pediatric patients with plaque psoriasis (PP).

Experts discuss plaque psoriasis (PP) treatment options for people who are or may become pregnant.

James Q. Del Rosso, DO, and Dawn L. Sammons, DO, FAOCD, FAAD, review the efficacy of a new topical agent in the treatment of plaque psoriasis, tapinarof, highlighting the remittive data.

Experts in dermatology discuss newer topical treatments, such as tapinarof, in the management of plaque psoriasis.

Expert dermatologists review the use of dupilumab for the treatment of AD, focusing on the once-monthly shot as a factor in selection.

Elizabeth Swanson, MD, and Brad Glick, DO, MPH, FAOCD, share treatment approaches for pediatric patients with AD.

Nicholas Brownstone, MD, comments on how newer treatments in plaque psoriasis can impact residency training.

Dawn L. Sammons, DO, FAOCD, FAAD, shares her approach to using topical vs systemic therapy in plaque psoriasis, focusing on patient preference as the driving factor for treatment selection.

Drs Justine Cohen and Brent Moody provide their key takeaways and panel discussion highlights related to the management of patients with basal cell carcinoma.

An expert in dermatology shares her insights into the duration of treatment and dose adjustments for systemic treatments in patients with basal cell carcinoma.

Dr Justine Cohen discusses her approach to systemic treatment selection in her patients with basal cell carcinoma; highlighting the importance of individualizing the treatment plan.

Justine Cohen, DO and Brent Moody M.D., F.A.C.P., F.A.A.D, comment on which patients would be appropriate for non-surgical treatment options in the management of their basal cell carcinoma.

Tj Chao, MPAS, and Lauren Miller, MPAS, highlight comorbidities that caregivers should consider when treating patients with plaque psoriasis (PP).

Lauren Miller, MPAS, and Tj Chao, MPAS, discuss key factors to consider for plaque psoriasis (PP) treatment.

Expert dermatologists present and share initial impressions of a patient case for a 6-year-old male with AD, highlighting the impact of sleep deprivation.

Jonathan I Silverberg, MD, PhD, MPH; Elizabeth Swanson, MD; Brad Glick, DO, MPH, FAOCD; and Andrew Blauvelt, MD, MBA, review factors that lead to switching therapies in AD, focusing on monotherapies vs combination therapy.

An expert in dermatology shares his opinion on the multiple formulations of isotretinoin and the importance of generic vs brand compositions.

Dr Leon Kircik, discusses the novel treatment Clascoterone cream 1%, an androgen receptor agonist, and the utility of this treatment in the management of acne.

Leon Kircik, MD, shares his opinion on the role and use of treatment guidelines by healthcare practitioners in the management of their patients.

Experts discuss the role and importance of physician assistants in the treatment and care of plaque psoriasis (PP).

Tj Chao, MPAS, and Lauren Miller, MPAS, discuss the symptoms of plaque psoriasis (PP) and why it may be difficult to diagnose.

Brad Glick, DO, FAOCD, highlights topical therapy as a targeted treatment of plaque psoriasis.

Benjamin Lockshin, MD, FAAD, comments on how the evolution of the pathophysiology of plaque psoriasis has led to more targeted therapies to treat the disease.

Experts in dermatology comment on how often quickness of response to therapy determines treatment selection for teenaged patients with AD.

Expert dermatologists discuss treatment selection for short-term rescue vs long-term maintenance therapy.

Christopher Bunick, MD, PhD, comments on the role isotretinoin plays in his practice and comments on further advancements in the management of this condition.

An expert in dermatology shares his opinion on oral versus topical acne treatment options and how to assess response to treatment.

Dr Christopher Bunick discusses the role the microbiome and sebum play in acne production and highlights the role Clascoterone cream 1% plays in targeting these agents.

Christopher Bunick, MD, PhD, provides an overview of acne vulgaris and the populations it impacts; highlighting that this is more than just an adolescent affliction and the role of sebum production.